The SERD Therapeutics Market Size is valued at 1508.0 Million in 2022 and is predicted to reach 6382.2 Million by the year 2031 at a 17.5 % CAGR during the forecast period for 2023-2031.
Selective estrogen receptor degrader (SERD) is a type of drug which downregulates the estrogen receptor. SERD treats estrogen receptor-positive breast cancer. SERD therapy can be used as both monotherapies and in combination with other therapeutic agents. Many key market players are engaged in developing new breast cancer therapies that would propel the growth of this market.
Major driving factors in the SERD therapeutics market are the increasing need for SERD therapies, the high prevalence of breast cancer, the rising number of clinical trials, and increasing investments by key players in the development of promising treatments. Furthermore, advanced medical technologies, growth in the population, and a growing number of health-conscious people will enhance the growth of the SERD therapeutics market during the forecast period. However, the high price of devices, complex procedures, lack of strict government laws, and resistance to endocrine Therapy are limiting the growth of this market.
Market Segmentation
The SERD therapeutics market is segmented into Products, Route of Administration, Indication and Region. On the basis of Products, market is segmented into Faslodex, Elacestrant, Camizestrant (AZD9833), Giredestrant (GDC-9545), Imlunestrant (LY3484356), Other Pipeline Products. The Route of Administration segments consists of Intramuscular, Oral, Infusion, Subcutaneous, Parenteral, and Other. On the basis of Indications, segment includes ER-positive, HER2-negative, ESR1-mutated, advanced or metastatic breast cancer and Other.
Regionally, the SERD therapeutics market is divided into North America, Europe, Asia-Pacific, Latin America, and the Middle East and Africa. North America, followed by Europe, holds the maximum share of this market due to increased research and development expenditure, major market players, and the fast adaption of advanced technologies.
Major vital Players in the SERD therapeutics market are Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, and List of Other Prominent Players.
Competitive Landscape
Some of The Key Players in The SERD Therapeutics Market:
- Amneal Pharmaceuticals Inc
- AstraZeneca, Plc.
- Reddy’s Laboratories
- Eli Lilly and Company
- G1 Therapeutics, Inc.
- Glenmark Pharmaceuticals
- HBT Labs, Inc
- Hoffmann-La Roche AG
- InventisBio
- Novartis AG
- Radius Health
- Sanofi S.A.
- Teva Pharmaceutical Industries Ltd.
- Zenopharm LLC.
- Zentalis Pharmaceuticals
- Genentech
- Olema Pharmaceuticals
- Aragon Pharmaceuticals
- Sun Pharma Advanced Research Company
- Shandong Luoxin Pharmaceutical
- Zeno Alpha
- Atossa Therapeutics
- Evestra
The SERD Therapeutics Market Report Scope
|
Report Attribute |
Specifications |
|
Market Size Value In 2022 |
USD 1508.0 Million |
|
Revenue Forecast In 2031 |
USD 6382.2 Million |
|
Growth Rate CAGR |
CAGR of 17.5 % from 2023 to 2031 |
|
Quantitative Units |
Representation of revenue in US$ Million and CAGR from 2023 to 2031 |
|
Historic Year |
2019 to 2022 |
|
Forecast Year |
2023-2031 |
|
Report Coverage |
The forecast of revenue, the position of the company, the competitive market structure, growth prospects, and trends |
|
Segments Covered |
By Products, By Route of Administration, By Indication |
|
Regional Scope |
North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
|
Country Scope |
U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico ;The UK; France; Italy; Spain; China; Japan; India; South Korea; South East Asia; South Korea; South East Asia |
|
Competitive Landscape |
Amneal Pharmaceuticals Inc, AstraZeneca, Plc., Dr. Reddy’s Laboratories, Eli Lilly and Company, G1 Therapeutics, Inc., Glenmark Pharmaceuticals, HBT Labs, Inc, Hoffmann-La Roche AG, InventisBio, Novartis AG, Radius Health, Sanofi S.A., Teva Pharmaceutical Industries Ltd., Zenopharm LLC., Zentalis Pharmaceuticals, Genentech, Olema Pharmaceuticals, Aragon Pharmaceuticals, Sun Pharma Advanced Research Company, Shandong Luoxin Pharmaceutical Zeno Alpha, Atossa Therapeutics, Evestra and Others. |
|
Customization Scope |
Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
|
Pricing And Available Payment Methods |
Explore pricing alternatives that are customized to your particular study requirements. |
